VOLUME 15 1991

SUBJECT INDEX

Absence epilepsy, 259
Acetylcholine, 299
Acetylcholinesterase, 123
Activity stress, 319
Acute toxicity, 95
Acute treatment, 539
Addiction, 425
Afterbirth, 425
Aggression, 497, 527, 539
Aggressive behavior, 439
Agonistic behavior, 521
Alcohol, 233, 265, 515
Alcohol-preferring rats, 265
Alertness, 259
All-or-none response, 47
Alpha-2 adrenergic agonists, 349
Amniotic fluid, 425
Amphetamine, 455
Amygdala, 363
Analgesia, 425, 489
Angiotensin, 265
Angiotensin converting enzyme inhibitor, 265
Anhedonia, 391
Animal model, 7, 25, 35, 115, 259, 461, 497
Animal models for screening psychotropic drugs, 439
Animal-to-man extrapolation, 165
Anorexia nervosa, 327
α_2 Antagonist, 505
Antiandrogens, 521
Anticholinergic, 141
Anticholinergic drugs, 349
Anticholinesterase, 141
Anticonvulsant, 349
Antidepressants, 391, 539
Antiepileptic drugs, 349
Antiestrogens, 521
Antitussives, 349
Anxiety, 461, 469, 473, 483, 489
Anxiolytics, 461
Apomorphine, 455
Area postrema, 265
Arousal, 259
Atropine, 51
Atropine sulfate, 21
Attack, 527

Baboons, 21
Barbiturates, 233, 349
Behavior, 217, 233
Behavioral assessment of drug action, 455
Behavioral dependence, 515
Behavioral toxicity, 35
Behaviour, 447
Benactyzine, 469
Benzodiazepines, 233, 349
Binding, 73
Binomial response, 129
Bioequivalence, 51
Blood-brain barrier, 243, 333
Body mass, 95
Body temperature, 95
Brain, 243
Brain damage, 349
Brain lesions, 341
Brown adipose tissue, 383
Buspirone, 483
Butyrylcholinesterase, 123

Calcium channel blockers, 349
Carbamate cholinesterase inhibitors, 349
Carboxylesterase, 85, 123, 135
Carboxylesterase inhibitors, 85
CCK receptor subtypes, 473
Central benzodiazepine receptor, 277
Central nervous system, 185, 243
Cerebrospinal fluid, 243
CGS 12066B, 489
Cholecystokinin, 473
Cholinergic receptors, 349
Cholinergic system, 299
Chronic treatment, 539
Circadian rhythm, 259
Circumventricular organs, 243
CNS depressants, 233
Communication, 383
Compartmental modeling, 57
Compulsive behaviour, 527
Concepts of ethopharmacology, 439
Conducting airways, 63
Convulsions, 349
Copulatory disorder, 497
Core temperature, 115
Cross-species extrapolation, 165
Cupric-silver stain, 89
Cytochrome P450, 105

Data acquisition, 447
Data extrapolation, 15
Defeat, 489, 497
Defense, 479, 489, 545
Defensive behavior, 439, 461, 469
Degeneration, 89
Delivery, 425
Depression, 391
Dermatotoxicity, 25
Detoxifying activities, 99
Diazepam, 159
Diethylnitrosamine, 99
Diffusion model, 57
DNA alterations, 99
DNA damage, 25
DNA strand breaks, 99
DOI, 483
Dominance rank, 515
Dopamine, 391, 473
Dose-response distribution, 109
Dosimetry, 63
Drug abuse, 35
Drug discrimination, 35
Drug interactions, 349
Drug self-administration, 35

Emesis, 179
Environmental stress, 277
Enzymes as pretreatment drugs, 123
Epilepsy, 79
Esterase, 85, 123
Estradiol, 407
Estrogen, 327
Ethology, 447
Ethopharmacology, 447, 521, 527
Etiology, 327
Evoked potentials, 159
Excitatory amino acids, 349
Exercise, 115, 141
Experimental models, 15
Exploratory activity tests, 473
External stimuli, 515
Extrapolation, 7, 57, 95, 115
Extrapolation to man, 25
Extreme percentiles, 109

Fear, 461
Feeding, 479
Feeding behavior, 341
Female sexual behaviour, 505
Fever, 383
Fickian equation, 57
Flow cytometry, 99
Fluprazine, 511
Fostering procedure, 501
Foxes, 545
Freud, 375

GABA, 233, 473
Gastric ulcer, 319
Gender differences, 469
Genotoxicity, 99
Gepirone, 483
Gestational benzodiazepine exposure, 501
GR 38032F, 483
Graphics, 447
Group sequential experimental designs, 129
Guinea pig, 73

Heart rate, 115
Heart rate fluctuations, 51
Hepatocytes, 105
HI-6, 349
Hippocampal slice, 79
Hippocampus, 363, 415
Histamine, 265
Histology, 89
History of ethopharmacology, 439
5-HT ligands, 489
5-HT_{1A} agonist, 505
Human, 21, 51, 95, 159, 179
Human models, 7
Hydrolysis, 73
5-Hydroxytryptamine, 375
Hypertension, 265
Hyperthermia, 141
Hypometabolism, 95
Hypothalamus, 527
Hypothermia, 95
Hypoxia, 79

ICI 169, 369, 489
Id, 375
Idazoxan, 505
Immune system, 185
Immunomodulators, 185

Immunopeptides, 185
Immunoregulators, 185
Influencing factors, 89
Inhalation, 233
Inhibition of aggression and infanticide, 511
Insulin, 243, 341
Interferons, 185
Interim analysis, 129
Interleukins, 185
Intermale attack, 511
Intracranial self-stimulation, 391
Intruder, 539
Ipsapirone, 483
Ischemia, 79
Isoproterenol, 265

Labor, 425
Laryngeal braking, 383
Legal and regulatory extrapolation, 149
Lethality, 349
Limbic system, 363
Linearity with dose, 73
Lithium, 105
Locomotor activity, 473
Locomotor behavior, 455
Long-term potentiation, 415
Lung casts, 63

Malathion, 149
Male mice, 497
Male sexual behaviour, 505
Mammals, 425
Manganese, 333
Marmoset, 73, 179
Mass balance, 57
Maternal behavior, 425, 501
MDL 73005EF, 489
Mean heart rate, 51
Measurement, 447
Medaka, 99
Membrane potentials, 407
Membrane receptors, 407
Memory, 299
MEPQ, 123
Mesocorticolimbic system, 391
Metabolic heat production, 383
Metabolic rate, 95
Methods, 447
5′-Methyldeoxycytidine, 99
Mice, 489, 511, 521, 545
Mink, 545
Mitochondria, 333
MK-212, 489
MK-801, 349
Model, 141
Model systems, 15
Morphine, 425
Motivation, 473
Mouse, 501
MPTP, 105
Muscarinic, 141

Naphthyl, 85
Neonate, 383
Nerve agent, 73
Neural mechanism, 545
Neurobehavioral toxicology, 153
Neurochemical changes, 277
Neuroendocrine, 327, 407
Neuroendocrine system, 185
Neurohypophyseal peptides, 217
Neuromuscular transmission, 25
Neuropeptides, 391
Neurotoxicity, 25, 89, 333
Nicotinic, 141
NMDA antagonists, 349
Nonshivering thermogenesis, 383
Nucleus accumbens, 473
Nucleus basalis magnocellularis, 299

Obesity, 341
Obsessive Compulsive Disorder, 375
OCD, 527
8-OH-DPAT, 483, 505
Open-field behavior, 455
Opioids, 425
Organic solvents, 233
Organophosphate toxicity, 123
Organophosphates, 85
Organophosphorus compounds, 349
Oxazepam, 501
Oxime protection, 135
Oxygen consumption, 115, 383
Oxytocin, 217

Pain, 425
Panic, 469
Paranitrophenyl, 85
Partial differential equation, 57
Parturition, 425
Patas monkey, 115
Paternal behavior, 511
Pattern adaptation, 159
PC computers, 447
Peptide, 243
Peripheral benzodiazepine receptor, 277
Perone, 483
Pharmacokinetics, 105
Physiological dependence, 35
Physiological stressor, 115
Physostigmine, 179
Pinacolyl methylphosphonofluoridate, 73
Placenta, 425
Placentophagia, 425
Plasticity, 415
Platelet activating factor, 185
POEF, 425
Predator, 479
Predatory aggression, 545
Pregnancy, 425
Prey killing, 511
Primate exercise wheel, 115
Primate models, 469
Proceptive behaviour, 505
Progesterone, 407, 521
Progestin receptors, 407
Prosexual effects, 505
Prostaglandin, 265
Pup killing, 511

Quantal response, 109
Quantification of species differences, 165
Quinine, 515
Quipazine, 483

Rat, 63, 73, 141, 159, 363, 383, 521, 527, 539, 545
Rat refractory period, 505
REM sleep, 259
REM sleep deprivation, 259
Renin-angiotensin system, 265
Repression, 375
Resident, 539
Respiration, 383
Respiratory sinus arrhythmias, 21
Restraint stress, 319
Review, 185, 243
Rhesus monkey, 21, 115, 173
Risk assessment, 15, 95, 153, 165, 461
Ritanserin, 483, 489

Sample size, 129
Sarin, 179
Satiety, 265
Scavenger, 123
Scientific extrapolation, 149
Secretion, 349
Selective vulnerability, 89
Sequential clinical trials, 129
Sequential drug screens, 129
Serenics, 527
Serial learning, 363
Serotonin, 265, 375, 461, 527, 545
Serotonin receptors, 489
Sex differences, 461
Sexual behavior, 407
Shock, 319
Sleep, 259
Social conflict, 497
Social interaction, 539
Soman, 73, 123, 135, 349
^{14}C-C(±)P(−)-soman, 73
^{14}C-C(±)P(+)-soman (labeled in P-CH_3 group), 73
Species differences, 105
Species variation, 135
Spectral analysis of heart rate, 51
Spiperone, 483
Spreadsheet, 447
Stagewise designs, 129
Stagewise experimental design, 109
Statistics, 447
Stepping, 455
Stereoisomers, 73
Stereospecificity, 73
Stereotyped behavior, 455
Stereotypies, 455
Stopping boundaries, 129
Stress, 319
Stressors, 391
Subfornical organ, 265
Superego, 375
Surface area, 95
Sweep VEP, 173

Temperature regulation, 141
Testing new chemical entities, 149
TFMPP, 483
Thermal balance, 115
Threshold estimation, 47
Tolerance, 425
Toluene, 153
Toxicity, 349
Toxicokinetics, 73
Toxicology, 7
Tranquillizers, 527
Transferrin, 333
Transport, 333
Trimethyltin, 79
Tuftsin, 185
Tumor necrosis factor, 185

Ulceration, 319
Ultrasonic calling, 483
Ultrasound, 383, 505
Up-and-down design, 47

Vagal tone, 21
Vagus nerve, 341
Variability, 63
Vasopressin, 217, 265
Venous exit condition, 57
Ventromedial hypothalamus, 341, 407
Vigilance, 259
Violence, 527
Vision, 159
Visual acuity, 173
Visual function, 173
Visual-evoked potential, 159, 173
Vocalisation, 469
VX, 123

Withdrawal, 425

Xenobiotic metabolism, 105

AUTHOR INDEX

Adani, N., 455
Akselrod, S., 51
Albanese, R. A., 57
Alberts, J. R., 383
Alcalay, M., 51
Alleva, E., 501
Alter, W. A. III, 3
Anisman, H., 391
Argiolas, A., 217
Armstrong, D. L., 79
Aschner, J. L., 333
Aschner, M., 333
Ashani, Y., 123

Balster, R. L., 233
Baudry, M., 415
Benignus, V. A., 165
Benjamini, Y., 51
Benschop, H. P., 73
Benton, D., 483
Bignami, G., 501
Blanchard, D. C., 461
Blanchard, R. J., 461
Bloetjes, K., 505
Blumberg, M. S., 383
Boyes, W. K., 159, 165
Brady, J. V., 35
Brain, P. F., 483, 521
Brecht, K. M., 135

Capacio, B. R., 349
Chambers, J. P., 85
Coenen, A. M. L., 259
Coffey, D. J., 173
Compton, D. M., 363
Connor, D. J., 299
Constable, S. H., 115
Crepeau, L. J., 469

De Jong, L. P. A., 73
Dekker, A. J. A. M., 299
Dellinger, J. A., 21
Delville, Y., 407
De Padua Carobrez, A., 461
Dews, P. B., 149
Dixon, W. J., 47
D'Mello, G. D., 179
Doctor, B. P., 123
Donát, P., 447, 489
Drinkenburg, W. H. I. M., 259
Drugan, R. C., 277

Evans, E. B., 233

Feder, P. I., 109, 129
Fletcher, A., 539
Frey, C. M., 165

Gardner, H., 99
Gessa, G. L., 217
Glickman, R. D., 173
Glowa, J. R., 153
Golani, I., 455
Gordon, C. J., 95
Grupp, L. A., 265

Harro, J., 473
Hartgraves, S. L., 3, 85
Haug, M., 483
Hendrie, C. A., 479
Hobson, D. W., 109, 129
Holmes, P. V., 277
Hudnell, H. K., 159, 165

Irving, G. W., III, 15
Izraeli, S., 51

Jenden, D. J., 105
Joiner, R. L., 109, 129

Katz, R. J., 375
Kimura, N., 497
King, B. M., 341
Kiryati, N., 455
Koviak, T. A., 349
Kristal, M. B., 425
Kršiak, M., 439
Kruk, M. R., 527
Kumar, N., 85

Laviola, G., 501

McCarthy, J. F., 99

Martińez, M., 521
Massicotte, G., 415
Matthew, C. B., 141
Matthews, M. C., 109, 129
Maxwell, D. M., 123, 135
Medina, R. L., 57
Ménache, M. G., 63
Miller, F. J., 63
Mitchell, P. J., 539
Mos, J., 505
Murison, R., 319
Murphy, M. R., 85

Nastiti, K., 483
Neill, J. C., 479
Newman, J. D., 469
Nikulina, E. M., 545

Olafsen, K., 319
Olivier, B., 505
Olson, C. T., 109, 129

Palanza, P., 511
Parmigiani, S., 511
Patra, A. L., 63
Peeters, B. W. M. M., 259
Perlanski, E., 265
Plata-Salamán, C. R., 185, 243

Raveh, L., 123
Redfern, P. H., 539
Rhodes, J. W., 173
Rodgers, R. J., 489
Russell, R. W., 7

Shepherd, J. K., 461, 489
Sherry, C. J., 115
Shih, T.-M., 349
Shugart, L. R., 99
Sidell, F. R., 179
Simón, V. M., 521
Stewart, R. B., 265
Svendsgaard, D. J., 165
Switzer, R. C., III, 89

Thal, L. J., 299
Tochner, Z., 51

Valdes, J. J., 85
Van Logten, K., 505
van Luijtelaar, E. L. J. M., 259
Vasar, E., 473
Vossen, J. M. H., 259

Wallach-Kapon, R., 51
Walters, T. J., 115
Wayner, M. J., 3, 85
Wolfe, A. D., 123
Wolfe, M. J., 99
Wolffgramm, J., 515
Wolthuis, O. L., 25

Yoshimura, H., 497
Young, J. K., 327

Zacharko, R. M., 391